» Articles » PMID: 31521629

Vascular Mineralocorticoid Receptor Activation and Disease

Overview
Journal Exp Eye Res
Specialty Ophthalmology
Date 2019 Sep 16
PMID 31521629
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Mineralocorticoid receptor activation in endothelial and smooth muscle cells can promote vascular disease by increasing oxidative stress, promoting inflammation, accelerating vascular stiffness, remodeling, and calcification, altering vessel responsiveness to various vasoactive factors, thus altering vascular tone and blood pressure, and by altering angiogenesis. Here, we review the recent evidence highlighting the impact of vascular mineralocorticoid receptor activation in pathological situations, including kidney injury, vascular injury associated with metabolic diseases, atherosclerosis, cerebral vascular injury during hypertension, vascular stiffening and aging, pulmonary hypertension, vascular calcification, cardiac remodeling, wound healing, inflammation, thrombosis, and disorders related to angiogenic defects in the eye. The possible mechanisms implicating mineralocorticoid receptor activation in various vascular disorders are discussed. Altogether, recent evidence points towards pharmacological mineralocorticoid receptor inhibition as a strategy to treat diseases in which overactivation of the mineralocorticoid receptor in endothelial and/or smooth muscle cells may play a pivotal role.

Citing Articles

Mineralocorticoid Receptor and Sleep Quality in Chronic Kidney Disease.

de la Puente-Aldea J, Lopez-Llanos O, Horrillo D, Marcos-Sanchez H, Sanz-Ballesteros S, Franco R Int J Mol Sci. 2024; 25(22).

PMID: 39596384 PMC: 11594958. DOI: 10.3390/ijms252212320.


Eight weeks of treatment with mineralocorticoid receptor blockade does not alter vascular function in individuals with and without type 2 diabetes.

Finsen S, Hansen M, Hansen P, Mortensen S Physiol Rep. 2024; 12(7):e16010.

PMID: 38610066 PMC: 11014871. DOI: 10.14814/phy2.16010.


Aldosterone: Renal Action and Physiological Effects.

Johnston J, Welch A, Cain B, Sayeski P, Gumz M, Wingo C Compr Physiol. 2023; 13(2):4409-4491.

PMID: 36994769 PMC: 11472823. DOI: 10.1002/cphy.c190043.


Emerging vascular cell-specific roles for mineralocorticoid receptor: implications for understanding sex differences in cardiovascular disease.

Wolter N, Jaffe I Am J Physiol Cell Physiol. 2022; 324(1):C193-C204.

PMID: 36440858 PMC: 9902217. DOI: 10.1152/ajpcell.00372.2022.


Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.

Kolkhof P, Lawatscheck R, Filippatos G, Bakris G Int J Mol Sci. 2022; 23(16).

PMID: 36012508 PMC: 9408839. DOI: 10.3390/ijms23169243.